Evaluation of oyster mushroom ( Pleurotus ostreatus )-derived anthraquinone on the induction of apoptosis and suppression of MMP-2 and MMP-9 expression in breast cancer cells.

Publisher: Ivyspring International Publisher Country of Publication: Australia NLM ID: 101213954 Publication Model: eCollection Cited Medium: Internet ISSN: 1449-1907 (Electronic) Linking ISSN: 14491907 NLM ISO Abbreviation: Int J Med Sci Subsets: MEDLINE

Original Publication: [Australia] : Ivyspring International Publisher, c2004-

Breast Neoplasms*/drug therapy ; Breast Neoplasms*/pathology ; Breast Neoplasms*/genetics ; Anthraquinones*/pharmacology ; Matrix Metalloproteinase 9*/metabolism ; Matrix Metalloproteinase 9*/genetics ; Apoptosis*/drug effects ; Apoptosis*/genetics ; Matrix Metalloproteinase 2*/genetics ; Matrix Metalloproteinase 2*/metabolism ; Pleurotus*/chemistry; Humans ; MCF-7 Cells ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Oxidative Stress/drug effects

Introduction : Breast cancer results from tissue degradation caused by environmental and genetic factors that affect cells in the body. Matrix metalloproteinases, such as MMP-2 and MMP-9, are considered potential putative markers for tumor diagnosis in clinical validation due to their easy detection in body fluids. In addition, recent reports have suggested multiple roles for MMPs, rather than simply degeneration of the extracellular matrix, which comprises mobilizing growth factors and processing surface molecules. Methods : In this study, the chemotherapeutic effects of anthraquinone (AQ) extracted from edible mushrooms ( Pleurotus ostreatus Jacq. ex Fr.) cells was examined in MCF-7 breast cancer cells. The cytotoxic potential and oxidative stress induced by purified anthraquinone were assessed in MCF-7 cells using MTT and ROS estimation assays. Gelatin Zymography, and DNA fragmentation assays were performed to examine MMP expression and apoptotic induction in the MCF-7 cells treated with AQ. The genes crucial for mutations were examined, and the mutated RNA knockout plausibility was analyzed using the CRISPR spcas9 genome editing software. Results : MCF-7 cells were attenuated in a concentration-dependent manner by the administration of AQ purified from P. ostreatus compared with the standard anticancer drug paclitaxel. AQ supplementation decreased oxidative stress and mitochondrial impairment in MCF-7 cells. Treatment with AQ and AQ with paclitaxel consistently decreased the expression of crucial marker genes such as MMP2 and MMP9 . The mutated genes MMP2 , MMP7 , and MMP9 were assessed and observed to reveal four putative gene knockdown potentials for breast cancer treatment. Conclusions : The synergistic application of AQ and paclitaxel exerted a strong inhibitory effect on the MCF-7 breast cancer cells. Extensive studies are imperative to better understand the action of bioactive mixes on the edible oyster fungus P. ostreatus . The gene knockout potential detected by CRISPR SpCas9 will aid in elite research into anticancer treatments.
Competing Interests: Competing Interests: The authors have declared that no competing interest exists.
(© The author(s).)

Biochem Biophys Res Commun. 1993 Nov 30;197(1):40-5. (PMID: 8250945)
Metabolites. 2022 Aug 31;12(9):. (PMID: 36144225)
Cancer Lett. 2006 Nov 28;244(1):61-70. (PMID: 16413114)
Cancer Biol Ther. 2006 Jan;5(1):97-103. (PMID: 16357514)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
BMC Cancer. 2021 Feb 10;21(1):149. (PMID: 33568081)
Int J Oncol. 2008 Dec;33(6):1307-13. (PMID: 19020765)
Exp Toxicol Pathol. 2013 Nov;65(7-8):1101-8. (PMID: 23735541)
Br J Pharmacol. 2010 Feb 1;159(3):689-97. (PMID: 20128807)
Methods. 2008 Mar;44(3):250-4. (PMID: 18314056)
Chem Biol Interact. 2012 Aug 30;199(2):129-36. (PMID: 22796323)
RNA Biol. 2013 May;10(5):679-86. (PMID: 23439366)
Curr Protoc Immunol. 2015 Nov 02;111:A3.B.1-A3.B.3. (PMID: 26529666)
Methods Mol Biol. 2010;594:57-72. (PMID: 20072909)
Glob Med Genet. 2023 Apr 17;10(2):48-53. (PMID: 37077369)
Pharmazie. 1995 Jun;50(6):441-2. (PMID: 7651988)
Drug Des Devel Ther. 2015 Feb 17;9:983-92. (PMID: 25733816)
J Med Food. 2006 Summer;9(2):196-204. (PMID: 16822205)
Pharmaceuticals (Basel). 2022 Jan 31;15(2):. (PMID: 35215289)
Cancers (Basel). 2023 Mar 17;15(6):. (PMID: 36980699)
BMC Complement Altern Med. 2018 Jan 27;18(1):31. (PMID: 29374471)
Chem Biol. 2015 Jan 22;22(1):107-16. (PMID: 25579209)
Appl Biochem Biotechnol. 2020 Jun;191(2):555-566. (PMID: 31820379)
Leuk Lymphoma. 2003 Nov;44(11):1957-62. (PMID: 14738150)
J Basic Clin Physiol Pharmacol. 2018 Jan 26;29(1):95-102. (PMID: 29127762)
Int J Oncol. 2021 May;58(5):. (PMID: 33760108)
Cell Cycle. 2018;17(6):766-779. (PMID: 29417873)
BMC Complement Altern Med. 2018 Jul 3;18(1):200. (PMID: 29970094)
Avicenna J Phytomed. 2019 May-Jun;9(3):237-247. (PMID: 31143691)
Oxid Med Cell Longev. 2016;2016:3685671. (PMID: 27057273)
Oncol Rep. 2006 Feb;15(2):417-23. (PMID: 16391863)

Keywords: Anthraquinone; CRISPR SpCas9; MCF-7 cells; Matrix metallo-proteinases; Pleurotus ostreatus

0 (MMP9 protein, human)
0 (MMP2 protein, human)

Date Created: 20240522 Date Completed: 20240522 Latest Revision: 20240607

20240608

PMC11103395

10.7150/ijms.93334

38774755